Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells

Molecular Cancer Research

Volumn 6, Issue 5, 2008, Pages 808-818

  Devlin, Hong Lin ^a   Mack, Phillip C ^a   Burich, Rebekah A ^a   Gumerlock, Paul H ^a   Kung, Hsing Jien ^a   Mudryj, Maria ^b   DeVere White, Ralph W ^b  

^a Cancer Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DOXORUBICIN; HISTONE H2AX; PROTEIN P53; PROTEIN P53 R2; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; RRM2B PROTEIN, HUMAN; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL IMMORTALIZATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; CELL CYCLE; CHEMISTRY; DOMINANT GENE; GENE EXPRESSION REGULATION; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, DOMINANT; GENES, P53; HUMANS; MALE; PROSTATIC NEOPLASMS; RIBONUCLEOTIDE REDUCTASES; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 51049105096     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-2027     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Sweat GT. Guiding prostate cancer treatment choices. Early detection means more options for more men. Postgrad Med 2005;117:45-50.
3. Pickett M, Bruner DW, Joseph A, Burggraf V. Prostate cancer elder alert. Living with treatment choices and outcomes. J Gerontol Nurs 2000;26:22-34;quiz 54-5.
4. Dewey WC, Ling CC, Meyn RE. Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys 1995;33:781-96.
5. Nunez MI, McMillan TJ, Valenzuela MT, Ruiz de Almodovar JM, Pedraza V. Relationship between DNA damage, rejoining and cell killing by radiation in mammalian cells. Radiother Oncol 1996;39:155-65.
6. Ross GM. Induction of cell death by radiotherapy. Endocr Relat Cancer 1999;6:41-4.
7. Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-501.
8. Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B. Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev 2000;14:1584-8.
9. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3δ is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401:616-20.
10. Ohki R, Nemoto J, Murasawa H, et al. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem 2000;275:22627-30.
11. Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000;404:42-9.
12. Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000;102:849-62.
13. Attardi LD, Reczek EE, Cosmas C, et al. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev 2000;14:704-18.
14. Offer H, Erez N, Zurer I, et al. The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA. Carcinogenesis 2002;23:1025-32.
15. Fei P, El-Deiry WS. P53 and radiation responses. Oncogene 2003;22:5774-83.
16. Yamaguchi T, Matsuda K, Sagiya Y, et al. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 2001;61:8256-62.
17. Yanamoto S, Iwamoto T, Kawasaki G, Yoshitomi I, Baba N, Mizuno A. Silencing of the p53R2 gene by RNA interference inhibits growth and enhances 5-fluorouracil sensitivity of oral cancer cells. Cancer Lett 2005;223:67-76.
18. Guittet O, Hakansson P, Voevodskaya N, et al. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 2001;276:40647-51.
19. Xue L, Zhou B, Liu X, Qiu W, Jin Z, Yen Y. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res 2003;63:980-6.
20. Xue L, Zhou B, Liu X, et al. Ribonucleotide reductase small subunit p53R2 facilitates p21 induction of G1 arrest under UV irradiation. Cancer Res 2007;67:16-21.
21. Nesslinger NJ, Shi XB, deVere White RW. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res 2003;63:2228-33.
22. Tepper CG, Gregg JP, Shi XB, et al. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Prostate 2005;65:375-89.
23. Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH, deVere White RW. Complex functions of mutant p53 alleles from human prostate cancer. Prostate 2002;51:59-72.
24. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999;18:477-85.
25. Fan S, el-Deiry WS, Bae I, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994;54:5824-30.
26. Stubbe J. Ribonucleotide reductases: the link between an RNA and a DNA world? Curr Opin Struct Biol 2000;10:731-6.
27. Kotova I, Chabes AL, Lobov S, Thelander L, Bjorklund S. Sequences downstream of the transcription initiation site are important for proper initiation and regulation of mouse ribonucleotide reductase R2 gene transcription. Eur J Biochem 2003;270:1791-801.
28. Lee Y, Vassilakos A, Feng N, et al. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res 2003;63:2802-11.
29. Desai AA, Schilsky RL, Young A, et al. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol 2005;16:958-65.
30. Manegold C, Zatloukal P, Krejcy K, Blatter J. Gemcitabine in non-small cell lung cancer (NSCLC). Invest New Drugs 2000;18:29-42.
31. Tu GC, Tu X. GTI-2501. Lorus therapeutics. Curr Opin Investig Drugs 2001;2:1467-70.
32. Lee Y, Vassilakos A, Feng N, et al. GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors. Int J Oncol 2006;28:469-78.
33. Finch RA, Liu M, Grill SP, et al. Triapine (3-aminopyridine-2- carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 2000;59:983-91.
34. Uramoto H, Sugio K, Oyama T, Hanagiri T, Yasumoto K. P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer. Anticancer Res 2006;26:983-8.
35. Okumura H, Natsugoe S, Yokomakura N, et al. Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2006;12:3740-5.
36. Byun DS, Chae KS, Ryu BK, Lee MG, Chi SG. Expression and mutation analyses of P53R2, a newly identified p53 target for DNA repair in human gastric carcinoma. Int J Cancer 2002;98:718-23.
37. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet 2003;34:440-5.
38. Okaichi K, Wang LH, Sasaki J, Saya H, Tada M, Okumura Y. A point mutation of human p53, which was not detected as a mutation by a yeast functional assay, led to apoptosis but not p21Waf1/Cip1/Sdi1 expression in response to ionizing radiation in a human osteosarcoma cell line, Saos-2. Int J Radiat Oncol Biol Phys 1999;45:975-80.
39. Kaneuchi M, Yamashita T, Shindoh M, et al. Induction of apoptosis by the p53-273L (Arg → Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax. Mol Carcinog 1999;26:44-52.
40. Bissonnette N, Hunting DJ. p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage. Oncogene 1998;16:3461-9.
41. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-9.
42. Schmidt M, Fan Z. Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells. Oncogene 2001;20:6164-71.
43. de La Fuente C, Santiago F, Chong SY, et al. Overexpression of p21(waf1) in human T-cell lymphotropic virus type 1-infected cells and its association with cyclin A/cdk2. J Virol 2000;74:7270-83.